You are here:

Daptomycin (Cubicin)


Following a full submission

Daptomycin (Cubicin) is accepted for restricted use within NHS Scotland for the treatment of complicated skin and soft tissue infections in adults.

Daptomycin should be restricted to use in patients with known or suspected methicillinresistant Staphylococcus aureus (MRSA) infection and on the advice of local microbiologists or specialists in infectious disease.

Daptomycin has a higher acquisition cost than some alternative treatments; it does not, however, require therapeutic drug monitoring.

Drug Details

Drug Name: Daptomycin (Cubicin)
SMC Drug ID: 248/06
Manufacturer: Chiron Biopharmaceuticals
Indication: Complicated skin and soft tissue infections in adults
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 April 2006